SCLC1 gene and cancer
The SCLC1 gene is located on the short arm of chromosome 3 and plays a significant role in small-cell lung cancer (SCLC), a particularly aggressive form of lung cancer that represents about 10 to 15 percent of all lung cancer cases. SCLC is often linked to exposure to airborne carcinogens, particularly from cigarette smoke, and is characterized by its rapid metastasis at the time of diagnosis. The SCLC1 gene is frequently deleted in lung cancer cells, and this deletion, noted in 93 percent of SCLC cases, suggests it may encode tumor suppressors crucial for regulating cell division and preventing cancer development.
SCLC tumors often express unique neuroendocrine markers, indicating that they may originate from neuroendocrine cells that differentiate into epithelial cells. Research has shown that alterations in certain oncogenes and the loss of the SCLC1 gene may disrupt normal cell signaling, contributing to the cancer's progression. Over the years, advancements in understanding the SCLC1 gene have led to improved diagnostic methods and treatment options. Researchers are exploring molecular subtypes of the SCLC1 gene, which has facilitated the identification of biomarkers for earlier diagnoses and allowed for more personalized treatment strategies. Overall, the relationship between the SCLC1 gene and SCLC highlights the complexities of cancer biology and the ongoing efforts in cancer research to enhance patient outcomes.
On this Page
Subject Terms
SCLC1 gene and cancer
ALSO KNOWN AS: Small-cell carcinoma of lung, small-cell lung cancer (SCLC), oat cell cancer
DEFINITION: The SCLC1 gene is located on a region on the short arm of chromosome 3 that is frequently deleted in neoplastic lung cells associated with small-cell carcinomas, cells of epithelial origin.
Significance: Between 10 and 15 percent of all lung cancers are classified as small cell lung cancer (SCLC). Small-cell carcinomas of the lung are most commonly associated with people exposed to airborne carcinogens, particularly those associated with cigarette smoke. This form of lung cancer is particularly aggressive and has undergone metastasis at the time of diagnosis. SCLC cells frequently express a number of unusual neuroendocrine markers, including dopa-decarboxylase (DDC), and evidence suggests that these cells originate from a form of neuroendocrine cells that differentiate into epithelial cells in the lung.
Cancer cells, in general, arise from mutations that disrupt the normal regulation of cell divisions, frequently at the level of internal cell signaling. The expression of neuroendocrine markers in SCLC neoplasms appears to affect the RHOA (ras homolog) family of genes, particularly the products that are part of the signaling mechanism that stimulates cell division. Other oncogenes also appear to be altered in cell lines originating from SCLC neoplasms.
Regulation of oncogenes in a cell, in part, involves the production of tumor suppressors, proteins that either regulate oncogene expression or serve as stop signals to prevent the cell from undergoing replication. The region of the short arm on chromosome 3 that is deleted, 3p14–23, and specifically the SCLC1 gene, appears to encode one or more tumor suppressors.
Deletions of this region of chromosome 3, the region which encodes the SCLC1 gene, appears to take place during the early stages of formation of the neoplasm. Whether the deletion is required for development of this form of cancer is unknown, but this specific mutation seems to occur in nearly all cases of SCLC that have been analyzed. The deletion occurred in 93 percent of SCLC cases but only 25 percent of non-SCLC instances, so it is evident it plays a critical role. The mechanism of the deletion is also unknown.
History: The presence of this particular deletion in small-cell carcinomas of the lung was first noted in 1982. Scientists had established a number of lung cancer cell lines in the laboratory, the purpose of which was to study characteristics unique to each group; twelve lines originated as SCLC cases. All were observed to have the same deletion on chromosome 3, while cells from other lines did not.
Advances have been made in understanding the relationship between the SCLC1 gene and SCLC that have improved diagnoses, treatment options, and outcomes. Medical researchers have begun to gain a more complete understanding of the gene profile of the SCLC1 gene, as well as its molecular subtypes. This more complete understanding has led to the investigation of more effective treatments. Researchers have also been able to locate specific biomarkers that have enabled an earlier diagnosis of SCLC. Understanding SCLC tumors' genomic and molecular profiles has allowed doctors to tailor treatments to individual patients.
Bibliography
“Lung Cancer - Small Cell.” MedlinePlus, 28 Aug. 2023, medlineplus.gov/ency/article/000122.htm. Accessed 26 June 2024.
Petersen, I et al. “Small-cell Lung Cancer is Characterized by a High Incidence of Deletions on Chromosomes 3p, 4q, 5q, 10q, 13q and 17p.” British Journal of Cancer, vol. 75.1, 1997, pp. 79-86, doi:10.1038/bjc.1997.13.
“Small Cell Lung Cancer Guide - Understanding SCLC.” American Cancer Society, 29 Jan. 2024, www.cancer.org/cancer/types/lung-cancer/if-you-have-small-cell-lung-cancer-sclc.html. Accessed 26 June 2024.
“Small Cell Lung Cancer Treatment (PDQ®).” National Cancer Institute, 23 May 2024, www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq. Accessed 26 June 2024.
Tian, Yanhua, et al. "Single-cell Transcriptomic Profiling Reveals the Tumor Heterogeneity of Small-cell Lung Cancer." Signal Transduction and Targeted Therapy, vol. 7, no. 1, 2022, pp. 1-16, doi.org/10.1038/s41392-022-01150-4. Accessed 26 June 2024.
Wang, Qian, et al. "SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 18, no. 1, 2023, p. 31, doi.org/10.1016/j.jtho.2022.10.002. Accessed 26 June 2024.
Whang-Peng, J et al. “Specific Chromosome Defect Associated with Human Small-cell Lung Cancer; Deletion 3p(14-23).” Science (New York, N.Y.), vol. 215.4529, 1982, pp. 181-2, doi:10.1126/science.6274023.